Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

US Food and Drug Administration Efforts to Support Pain Management and Opioid Access to Patients With Cancer.

Hertz SH, Throckmorton DC.

J Oncol Pract. 2019 May;15(5):233-234. doi: 10.1200/JOP.19.00143. Epub 2019 Apr 23. No abstract available.

PMID:
31013179
2.

Storage and Disposal of Opioid Analgesics.

Liberatore MA, Racoosin JA, Throckmorton DC.

Ann Intern Med. 2019 Mar 19;170(6):431-432. doi: 10.7326/L18-0694. No abstract available.

PMID:
30884509
3.

Combined Gabapentinoid and Opioid Use: The Consequences of Shifting Prescribing Trends.

Throckmorton DC, Woodcock J.

Ann Intern Med. 2018 Nov 20;169(10):727-728. doi: 10.7326/M18-2175. Epub 2018 Aug 21. No abstract available.

PMID:
30140901
4.

The FDA and the Next Wave of Drug Abuse - Proactive Pharmacovigilance.

Throckmorton DC, Gottlieb S, Woodcock J.

N Engl J Med. 2018 Jul 19;379(3):205-207. doi: 10.1056/NEJMp1806486. Epub 2018 May 30. No abstract available.

5.

Medication development in opioid addiction: Meaningful clinical end points.

Volkow ND, Woodcock J, Compton WM, Throckmorton DC, Skolnick P, Hertz S, Wargo EM.

Sci Transl Med. 2018 Mar 28;10(434). pii: eaan2595. doi: 10.1126/scitranslmed.aan2595. Review.

PMID:
29593105
6.

The FDA's Approach to the Prescription Opioid Problem.

Woodcock J, Throckmorton DC.

Clin Pharmacol Ther. 2018 Jun;103(6):954-955. doi: 10.1002/cpt.1055. Epub 2018 Mar 23.

PMID:
29570773
7.

Effect of US Drug Enforcement Administration's Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing.

Jones CM, Lurie PG, Throckmorton DC.

JAMA Intern Med. 2016 Mar;176(3):399-402. doi: 10.1001/jamainternmed.2015.7799. No abstract available.

PMID:
26809459
8.

Shortage of Peritoneal Dialysis Solution and the Food and Drug Administration's Response.

Jensen V, Throckmorton DC.

Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1484-6. doi: 10.2215/CJN.12061214. Epub 2015 Apr 20.

9.

Expanded access to opioid overdose intervention: research, practice, and policy needs.

Compton WM, Volkow ND, Throckmorton DC, Lurie P.

Ann Intern Med. 2013 Jan 1;158(1):65-6. doi: 10.7326/0003-4819-158-1-201301010-00013. No abstract available.

PMID:
23277902
10.

Management of opioid analgesic overdose.

Throckmorton DC, Compton WM, Lurie P.

N Engl J Med. 2012 Oct 4;367(14):1371; author reply 1372-3. doi: 10.1056/NEJMc1209707. No abstract available.

PMID:
23034041
11.

A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients.

Florian J, Garnett CE, Nallani SC, Rappaport BA, Throckmorton DC.

Clin Pharmacol Ther. 2012 Apr;91(4):666-72. doi: 10.1038/clpt.2011.273. Epub 2012 Feb 29.

PMID:
22378153
12.

Adverse effects in women: implications for drug development and regulatory policies.

Parekh A, Fadiran EO, Uhl K, Throckmorton DC.

Expert Rev Clin Pharmacol. 2011 Jul;4(4):453-66. doi: 10.1586/ecp.11.29. Review.

PMID:
22114855
13.

Injectable extended-release naltrexone for opioid dependence.

Throckmorton DC, Temple R, Rappaport BA, Roca R, Winchell CJ.

Lancet. 2011 Aug 20;378(9792):665-6; author reply 666. doi: 10.1016/S0140-6736(11)61332-9. No abstract available.

PMID:
21856478
14.

How a US regulator can encourage new science.

Throckmorton DC.

Clin Pharmacol Ther. 2009 Nov;86(5):471-2. doi: 10.1038/clpt.2009.188.

PMID:
19844222
15.

The risks associated with short-term placebo-controlled antihypertensive clinical trials: a descriptive meta-analysis.

DeFelice A, Willard J, Lawrence J, Hung J, Gordon MA, Karkowsky A, Targum S, Throckmorton DC, Girton J, Stertz B, Glasser SP, Lipicky RJ.

J Hum Hypertens. 2008 Oct;22(10):659-68. doi: 10.1038/jhh.2008.51.

PMID:
18528409
16.

Drug interaction studies: study design, data analysis, and implications for dosing and labeling.

Huang SM, Temple R, Throckmorton DC, Lesko LJ.

Clin Pharmacol Ther. 2007 Feb;81(2):298-304. Review.

PMID:
17259955
17.

Regulatory advice on evaluation of the proarrhythmic potential of drugs.

Stockbridge N, Throckmorton DC.

J Electrocardiol. 2004;37 Suppl:40-1. No abstract available.

PMID:
15534791
18.

Future trials of antiplatelet agents in cardiac ischemia.

Throckmorton DC.

N Engl J Med. 2001 Jun 21;344(25):1937-9. No abstract available.

PMID:
11419432
19.

Protein kinase C activation during Ca2+-independent vascular smooth muscle contraction.

Throckmorton DC, Packer CS, Brophy CM.

J Surg Res. 1998 Jul 15;78(1):48-53.

PMID:
9733617
20.

Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes.

Beuers U, Throckmorton DC, Anderson MS, Isales CM, Thasler W, Kullak-Ublick GA, Sauter G, Koebe HG, Paumgartner G, Boyer JL.

Gastroenterology. 1996 May;110(5):1553-63.

PMID:
8613063
21.

Type I A-kinase is activated by platelet-derived growth factor in mesangial cells.

Throckmorton DC, Dickinson M, Dransfield DT.

Biochem Biophys Res Commun. 1996 Mar 27;220(3):692-6.

PMID:
8607827
22.

PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products.

Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M.

Kidney Int. 1995 Jul;48(1):111-7.

23.

Serotonin activates phospholipase D in rat mesangial cells.

Kurscheid-Reich D, Throckmorton DC, Rasmussen H.

Am J Physiol. 1995 Jun;268(6 Pt 2):F997-1003.

PMID:
7611466
24.

Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells.

Takeuchi A, Throckmorton DC, Brogden AP, Yoshizawa N, Rasmussen H, Kashgarian M.

Am J Physiol. 1995 Jan;268(1 Pt 2):F13-9.

PMID:
7840239
26.

Pseudohypoaldosteronism: case report and discussion of the syndrome.

Throckmorton DC, Bia MJ.

Yale J Biol Med. 1991 May-Jun;64(3):247-54.

Supplemental Content

Loading ...
Support Center